Anticancer Res

1. ANZELLINI D, Loddo M, Del Bianco S
   Long-lasting Complete Remission Following Immunotherapy With Anti-PD1 Plus Anti-CTLA4 in a Polymetastatic Patient With NRAS (Q16R) Mutated Anaplastic Thyroid Carcinoma.
   Anticancer Res. 2025;45:3809-3816.
   

   >> Share

   
   

   
   J Clin Endocrinol Metab

2. CHUBB SAP, Davis WA, Davis TME
   Effects of subclinical hypothyroidism on nephropathy complicating type 2 diabetes: The Fremantle Diabetes Study Phase II.
   J Clin Endocrinol Metab. 2025 Aug 29:dgaf485. doi: 10.1210.
   

   >> Share

   
   

   
   J Endocrinol Invest

3. HAI Y, Ma Q, Huang A, Fang S, et al
   Bibliometrics in thyroid eye disease.
   J Endocrinol Invest. 2025 Aug 29. doi: 10.1007/s40618-025-02688.
   

   >> Share

   
   

   
   J Nucl Med

4. UPRIMNY C, von Guggenberg E, Sviridenko A, Bayerschmidt S, et al
   Diagnostic Performance of the (68)Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine Tumors.
   J Nucl Med. 2025 Aug 28:jnumed.125.269863. doi: 10.2967/jnumed.125.269863.
   

   >> Share

   
   

   
   Nat Rev Endocrinol

5. WARD LS, Cunha LL
   Redefining thyroid cancer management.
   Nat Rev Endocrinol. 2025 Aug 26. doi: 10.1038/s41574-025-01173.
   

   >> Share

   
   

   
   PLoS One

6. LI Y, Li H, Sun Q, Long Q, et al
   A disproportionality analysis of FDA adverse event reporting system (FAERS) events for methimazole and propylthiouracil.
   PLoS One. 2025;20:e0328889.
   

   >> Share

   
   

   
   Thyroid

7. RAMCHANDANI R, Guo E, Biglou SG, Sabbah SG, et al
   Representation and Bias in Artificial Intelligence Models for Thyroid Cancer: A Systematic Review.
   Thyroid. 2025 Aug 28. doi: 10.1177/10507256251372175.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share